UroGen Pharma

Company Overview

Snapshot

Founded in April 2004 by Asher Holtzer, UroGen Pharma operates with 201–500 employees. The company has raised a total of $522.2 million across 11 funding rounds from 8 investors. In June 2024, UroGen Pharma announced the pricing of a public offering of ordinary shares and pre-funded warrants on NASDAQ.

Business overview

UroGen Pharma is a biotech company focused on developing novel solutions for specialty cancers and urologic diseases. The company utilizes its proprietary RTGel, a sustained-release, hydrogel-based platform technology, to enhance the therapeutic profiles of existing drugs by enabling longer exposure of the urinary tract tissue to medications. UroGen's lead product candidates, UGN-101 and UGN-102, are designed for non-surgical tumor removal and treatment of non-muscle-invasive urothelial cancer, including low-grade upper-tract urothelial carcinoma and bladder cancer. The company operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, targeting patients and healthcare providers.

Strategic signal

In October 2024, UroGen announced the FDA's acceptance of its New Drug Application for UGN-102, a significant regulatory milestone that validates the potential of its non-surgical treatment for bladder cancer. This acceptance signals strong progress in bringing innovative therapies to market and could significantly impact the treatment landscape for non-muscle-invasive urothelial cancer, demonstrating the company's capability to advance its pipeline through critical regulatory stages.

Company Intelligence Q&A

What was a key regulatory achievement for UroGen Pharma in October 2024?

In October 2024, the FDA accepted UroGen Pharma's New Drug Application for UGN-102, a treatment for bladder cancer, marking a significant step towards potential market approval.

What was the outcome of the ENVISION trial for UGN-102, published in October 2024?

In October 2024, results from the ENVISION trial published in The Journal of Urology reported an 82.3% duration of response 12 months after achieving complete response for UGN-102, indicating its potential as the first FDA-approved non-surgical treatment for LG-IR-NMIBC.

What recent financial activity did UroGen Pharma undertake in June 2024?

In June 2024, UroGen Pharma announced the pricing of a public offering of ordinary shares and pre-funded warrants on NASDAQ.

What was a notable development regarding UGN-103 in November 2025?

In November 2025, UroGen reported a 77.8% three-month complete response rate from the Phase 3 UTOPIA Trial of UGN-103 and received FDA agreement on the NDA submission strategy for recurrent LG-IR-NMIBC based on this trial.

What was the status of UGN-102's NDA submission following a Pre-NDA meeting with the FDA in October 2023?

Following a Pre-NDA meeting with the FDA in October 2023, UroGen Pharma announced that the rolling NDA submission for UGN-102 was set to begin in January 2024.